CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 46 enrolled
Drug / intervention
Erlotinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02961374
NCT02961374Phase 2Completed
CompareCT.gov

Phase II Trial of Weekly Erlotinib Dosing to Reduce Duodenal Polyp Burden Associated With Familial Adenomatous Polyposis

National Cancer Institute (NCI)·interventional·Posted Nov 11, 2016·Updated Jul 26, 2022

In Brief

A Phase 2 clinical trial evaluating Erlotinib and Erlotinib Hydrochloride for Attenuated Familial Adenomatous Polyposis and Familial Adenomatous Polyposis. Completed, enrolled 46 participants across 8 sites in 2 countries.

Detailed Summary

This phase II trial studies the side effects of erlotinib hydrochloride and how well it works in reducing duodenal polyp burden in patients with familial adenomatous polyposis at risk of developing colon cancer. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttenuated Familial Adenomatous Polyposis, Familial Adenomatous Polyposis
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 11, 2016
Enrollment StartOct 27, 2017
Primary CompletionFeb 23, 2020
Study CompletionSep 27, 2021
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 9.6 years ago

Interventions

Erlotinibdrug

Given PO

Erlotinib Hydrochloridedrug

Given PO